MOLECULAR-BIOLOGICAL FEATURES OF OVARIAN CANCER PATIENTS WITH AGGREGATION OF CANCER IN PEDIGREES
Keywords:
ovarian cancer, family history of cancer, the expression of biomolecular markers p53, BRCA1, Ki-67, microvessel density, steroid hormone receptors.Abstract
Summary. Aim: determining expression of biomolecular
markers in tumor tissue of patients with serous ovarian cancer (OC) with different types of cancer aggregation in pedigrees. Object and methods: 39 samples of surgical specimens of patients with ОС (average age 49.9 ± 8.0 years)
with III–IV stages of tumor, including 24 patients (group
I) were healthy relatives, 8 (group II) — aggregation in
the pedigrees of breast or ovarian cancer (BC/OC) and 7
(group III) — aggregation in relatives of endometrial or
gastrointestinal cancer (EC/GIC). Animmunohistochemical study of p53 and BRCA1 proteins, estrogen and progesterone receptors (ER and PR), a marker of proliferating
cells — Ki-67 and microvessel density were investigated.
Results: it was showed that, nuclear localization of protein BRCA1 were observed in tumors of 9 (23.7%) patients
with sporadic forms of OC and in 2 patients (5.3%) of aggregation in pedigrees EC/GIC and not detected in the tumors of patients with BC/OC accumulation in pedigrees.
The greatest number of tumor cells with p53-expressing
identified in the patients of second group (48.8 ± 2.5%)
compared the patients of first (34.6 ± 1.4%,) and third
(17.8± 1.8%) groups. The frequency of tumors with negative receptor phenotype (ER−PR−) by expressing estrogens
and progesterone receptors in the first, second and third
groups were 33.3; 50.0 and 28.6%, the average number
of proliferating cells, respectively, 25.9 ± 1.4; 32.2 ± 2.7
and 33.1 ± 2.8%. Microvessel density in tumors respectively, 71.3 ± 2.9; 64.4 ± 2.1 and 38.6 ± 1.8 vessels on
1 mm2
of tumor. Conclusion: it was found that of phenotypic specifications of the tumors of OC patients are associated with their family history on cancer and can reflect the characteristics of pathogenic changes that precede
the emergence of the disease and be predictive indicator
of survival of patients. The identified differences must be
considered, when assigning with OC patients personalized
anticancer therapy
References
Рак в Україні, 2013–2014. Захворюваність, смертність, показники діяльності онкологічної служби. Бюл. Нац. канцер-реєстру України, 2015; (16): 106 с.
Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and risk factors of ovarian cancer: a survey in primary care. Obstetrics Gynecol 2012, Article ID 754197, doi:10.5402/2012/754197.
Ашрафян ЛА, Киселев ВИ. Опухоли репродуктивных органов (этиология и патогенез). М.: Изд-во Димитрейд График Групп, 2007. 214 с.
Воробьева ЛИ, Свинцицкий ВС, Ткаля Г. Гормональный канцерогенез иобоснование применения гормональной терапии в лечении больных раком яичника. Клин Онкол 2013; 1: 58–64.
Прокофьева ДС. Изучение генетических факторов риска развития рака яичников [Автореф дис... канд биол наук]. Уфа, 2013. 23 с.
Соломатина АА, Шабрина ОВ, Ширинова СС, Саргсян НС. Значение факторов риска в диагностике яичниковых
образований Вестн РГМУ 2007; 4: 34–41.
Hecht JL, Kotsopoulos J, HankinsonSE, Tworoger SS. Relationship between epidemiological risk factors and hormone receptor expression in ovarian cancer: results from the Nurses’ Health Study. Cancer Epidemiol Biomarkers Prev 2009; 18 (5): 1624–30.
Arias-Pulido H, Smith HO, Joste NE, et al. Еstrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009; 114 (3): 480–5.
Buchynska LG, Iurchenko NP, Grinkevych VM, et al. Expression of the estrogene and progesterone receptors as prognostic factor in serous ovarian cancer. Exp Oncol 2009; 31 (1): 48–52.
Kruchten M, Marel P, Munck L, et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol 2015; 138 (3): 634–9.
Бучинська ЛГ, Глущенко НМ, Несина ИП, Юрченко НП. Возникновение злокачественных новообразований
у больных раком яичников. Онкол журн 2016; 10 (4): 70–6.
Russo A, Calò V, Bruno L, et al. Hereditary ovarian cancer. Critical Reviews. Oncol/Hematol 2009; 69: 28–44.
Ford D, Easton DF, Strution M, et al.Genetic heterogeneity and penetrance analyses of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676–89.
Любченко ЛН, Батенева ЕИ. Медико-генетическое консультирование и ДНК-диагностика при наследственной предрасположенности к раку молочной железы и раку яичников. Москва: ИГ РОНЦ, 2014. 75 с.
Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 2013; 24 (Suppl 10): 16–21.
Bаі X, Fu Y, Xue H, et al. BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with
low expression of BRCA1, improved survival and co‑expression of DNA methyltransferases. Oncol Letters 2014; 7: 1088–96.
Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 2013; 95 (2): 235–41.
Shivakumar S, Shobha HR, Kaur J. Correlation of сlinicopathological parameters of epithelial ovarian carcinomas with expression of p53. Int J Sci Stud 2015; 3 (2): 85–90.
Pothuri B, Leitao MM, Levine DA, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma 2010; 5 (4): е10358.
MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002; 22 (12): 4280–92.
Feng Z, Kachnic L, Zhang J, еt al. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 2004; 279
(27): 28574–84.
Lancaster JM, Powell CB, Chen L, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncol 2015; 136: 3–7.
Федянин МЮ. Персонализированная терапия в онкологии: настоящее и будущее. J Malign Tumor (Русскоязычное издание) 2012; 2 (2): 106–10.
Kashima K, Oite T, Aoki Y, et al. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 2000; 91: 399–409.
Troudi W, Uhrhammer N, Ben Romdhane K, et al. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? Eur J Histochem 2007; 51 (3): 219–26.
Бучинська ЛГ, Грінкевич ВМ, Свінціцький ВС, Романенко ОВ. Використання бімолекулярних маркерів для предикативної оцінки індивідуального прогнозу виживаності хворих на серозний рак яєчника. Онкология 2013; 15 (1): 37–9.
Lynch HT, Casey MJ, Snydera CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3 (2): 97–137.
Берштейн ЛМ. Гормональные и прогностические аспекты — BRCA1-ассоциированного канцерогенеза. Вопр онкол 2007; 53 (6): 642–53.
Wang Li, Di Li-Jun. BRCA1 аnd еstrogen/estrogen receptor in breast cancer: where they interact? Int J Biol Sci 2014; 10 (5): 566–75.
Несина ИП, Юрченко НП, Свинцицкий ВС, Бучинская ЛГ. Биологические особенности — серозного рака яичников с учетом экспрессии белка р53 и его модуляторов. Онкология 2015; 17 (4): 246–52.
Несіна ІП, Романенко ОВ, Грінкевич ВМ та ін. Прогностичне значення щільності мікросудин у серозних аденокарциномах яєчника. Онкологія 2008; 10 (2): 238–41.
Huang J, Hu W, Sood AK. Prognostic вiomarkers in оvarian сancer. Cancer Biomark 2010; 8: 231–51.
